Related Experiment Video
Updated: Jun 17, 2026

Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis
Published on: May 12, 2023
Adjuvants in tuberculosis vaccine development
Silvia A Moreno-Mendieta1, Leticia Rocha-Zavaleta, Romina Rodriguez-Sanoja
1Departamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), Ciudad Universitaria, México D.F., Mexico.
New tuberculosis vaccines are urgently needed as the current BCG vaccine is ineffective in adults. Adjuvants are crucial for the success of novel recombinant and DNA vaccines against tuberculosis.
Area of Science:
- Immunology
- Vaccinology
- Public Health
Background:
- Tuberculosis (TB) is a significant global health challenge.
- The existing Bacilli-Calmette-Guerin (BCG) vaccine offers limited protection against adult pulmonary TB.
- Novel vaccine strategies are essential to combat TB effectively.
Purpose of the Study:
- To review the current landscape of adjuvant development for tuberculosis vaccines.
- To assess the impact of adjuvants on the progress of new TB vaccine formulations.
- To highlight promising adjuvant and delivery system combinations for human use.
Main Methods:
- Literature review of recent advancements in TB vaccine research.
- Analysis of immunopathology and molecular techniques in vaccine development.
- Evaluation of adjuvant efficacy in preclinical and clinical studies.
Main Results:
- Recombinant and DNA-based TB vaccines require adjuvants for efficacy.
- Advances in understanding TB immunopathology have guided adjuvant selection.
- Promising adjuvant combinations are emerging for TB vaccine delivery.
Conclusions:
- Adjuvant development is critical for advancing tuberculosis vaccine candidates.
- Improved adjuvant formulations hold promise for effective TB prevention.
- Further research into adjuvant-TB vaccine combinations is warranted.
More Related Videos
07:32Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection
Published on: September 1, 2023
09:03Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
Published on: June 19, 2018
Related Concept Videos
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Tuberculosis